Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Jun;9(6):415-28.
doi: 10.1038/nrc2644.

The biology of ovarian cancer: new opportunities for translation

Robert C Bast Jr  1 , Bryan Hennessy, Gordon B Mills
Affiliations
Review

The biology of ovarian cancer: new opportunities for translation

Robert C Bast Jr et al. Nat Rev Cancer. 2009 Jun.

Abstract

Over the past two decades, the 5-year survival for ovarian cancer patients has substantially improved owing to more effective surgery and treatment with empirically optimized combinations of cytotoxic drugs, but the overall cure rate remains approximately 30%. Many investigators think that further empirical trials using combinations of conventional agents are likely to produce only modest incremental improvements in outcome. Given the heterogeneity of this disease, increases in long-term survival might be achieved by translating recent insights at the molecular and cellular levels to personalize individual strategies for treatment and to optimize early detection.

PubMed Disclaimer

Conflict of interest statement

Competing interests statement

The authors declare no competing financial interests.

References

    1. Goff BA, et al. Ovarian carcinoma diagnosis. Cancer. 2000;89:2068. - PubMed
    1. Zebrowski BK, et al. Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann. Surg. Oncol. 1999;6:373. - PubMed
    1. Mesiano S, Ferrara N, Jaffe R. Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am. J. Path. 1998;153:1249. - PMC - PubMed
    1. Numnum TM, et al. The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian cancer. Gynecol. Oncol. 2006;102:425. - PubMed
    1. Berek JS. In: Practical Gynecologic Oncology 4th edn Ch. 11 Ovarian Cancer. Berek JS, Hacker NF, editors. Philadelphia: Lippincott Williams & Wilkins; 2005. pp. 443–511.

Publication types

Substances